Kakamigahara, Japan

Katsunobu Osada



Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Katsunobu Osada: Innovator in Therapeutic Agents

Introduction

Katsunobu Osada is a notable inventor based in Kakamigahara, Japan. He has made significant contributions to the field of therapeutics, particularly addressing inflammatory diseases and autoimmune conditions through his innovative research and inventions.

Latest Patents

Osada holds one patent titled “Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine.” This invention presents salts and crystals that demonstrate excellent cell adhesion inhibitory action and cell infiltration inhibitory action. These properties make them valuable as therapeutic or prophylactic agents for a range of inflammatory diseases, such as inflammatory bowel disease (including ulcerative colitis and Crohn's disease), irritable bowel syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, asthma, and atopic dermatitis.

Career Highlights

Katsunobu Osada is affiliated with Eisai R&D Management Co., Ltd., where he conducts his research and develops innovative therapeutics. His dedication to addressing crucial health challenges through scientific innovation has earned him recognition in his field.

Collaborations

Throughout his career, Osada has collaborated with esteemed coworkers such as Makoto Kotake and Naoki Yoneda. These partnerships have been instrumental in enhancing the research quality and breadth of their projects, leading to valuable advancements in therapeutic solutions.

Conclusion

Katsunobu Osada stands out as a pioneering inventor whose work has the potential to transform treatment approaches for various inflammatory and autoimmune diseases. His commitment to scientific research and collaboration underlines the importance of innovation in the healthcare sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…